SubHero Banner

Keytruda®(pembrolizumab) – Expanded indication

March 21, 2022 - Merck announced the FDA approval of Keytruda (pembrolizumab), as a single agent, for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Download PDF